Tirzepatide 10mg
€69,99
Skip to product information
Tirzepatide 10mg
€69,99
Tirzepatide is a novel therapeutic agent developed to enhance glycemic control in adults with type 2 diabetes. By targeting multiple metabolic pathways, it assists in the regulation of blood sugar levels and may contribute to effective weight management. This treatment offers an advanced approach for patients seeking metabolic optimization under clinical supervision.
Tirzepatide 10 mg lyophilized powder (>99% purity) in a 3 ml vial. *Requires reconstitution with a solvent such as BAC Water
Specifications
| Name | Tirzepatide |
| Type | Research Peptide: Dual GIP/GLP-1 Receptor Agonist |
| Amino Acid Count | 39 |
| Purity | ± 99% (HPLC – COA available) |
| Molecular Weight | 4813.53 g/mol |
| Analyses | HPLC, MS, LC-MS |
| Format | Lyophilized powder |
| Storage Conditions | 2-8°C (short term) or -20°C (long term) |
Confidential Lab Data - Specification Sheet
Chemical Formula
C225H348N48O68
Tirzepatide Amino Acid Sequence (39 Amino Acids)
1Tyr
2Aib
3Glu
4Gly
5Thr
6Phe
7Thr
8Ser
9Asp
10Tyr
11Ser
12Ile
13Aib
14Leu
15Asp
16Lys
17Ile
18Ala
19Gln
20Lys*
21Ala
22Phe
23Val
24Gln
25Trp
26Leu
27Ile
28Ala
29Gly
30Gly
31Pro
32Ser
33Ser
34Gly
35Ala
36Pro
37Pro
38Pro
39Ser
*Lys20 is modified with a C20 fatty acid diacid moiety via a linker.
Tirzepatide: The Dual Metabolic Powerhouse
Tirzepatide is currently one of the most successful compounds for the management of type 2 diabetes and obesity. It is often regarded as the "golden mean": more potent than standard GLP-1 agents, yet backed by more established long-term safety data than the newest experimental agonists.
Origins: The Evolution of "Twincretins"
Developed by Eli Lilly, Tirzepatide represents a major leap in endocrine research.
• The Breakthrough: Researchers discovered that the satiety hormone GLP-1 works significantly better when combined with a second hormone: GIP.
• The Design: Tirzepatide is a single molecule engineered to bind to both receptors simultaneously. It is not a mixture of two separate drugs, but one intelligently designed "key" that fits into two different biological "locks."
• Current Status: Unlike newer experimental peptides, Tirzepatide has already received full regulatory approval from major health authorities such as the FDA and EMA.
Dual Mechanism of Action
The efficacy of Tirzepatide is derived from the synergistic interaction between two metabolic pathways:
1. GLP-1 (Glucagon-like Peptide-1)
Acting as the primary "appetite brake":
• It delays gastric emptying, prolonging the feeling of fullness after meals.
• It signals satiety to the brain, effectively reducing "food noise" and cravings.
2. GIP (Glucose-dependent Insulinotropic Polypeptide)
The "metabolic helper":
• GIP enhances how the body processes sugars and lipids.
• Research suggests that the addition of GIP may mitigate common gastrointestinal side effects associated with GLP-1, while simultaneously stimulating lipid metabolism directly in adipose tissue.